Skip to content
Oral Suspension Allopathic

Ulrif 1 gm/5 ml oral suspension

Generic: Sucralfate

Company: Not listed yet. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength1 gm/5 ml
PackOne bottle

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per oral suspension. Ask your pharmacist before you switch brands.

Sucralfate 1 gm/5 ml oral suspensions

Prices as listed on BestinMeds.

2 brands listed
Ulfate, 200.00 ml2.00 taka per oral suspension
Ulrif, 200.00 ml (this medicine)2.00 taka per oral suspension

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Sucralfate guide

Indications

Peptic ulcer disease Sucralfate is indicated in adults and adolescents over 14 years old for treatment of- Duodenal ulcer Gastric ulcer Chronic gastritis The prophylaxis of gastrointestinal hemorrhage from stress ulceration in seriously ill patients.

Dosage and administration

Duodenal ulcer, gastric ulcer, chronic gastritis- Adults: The usual dose is Sucralfate 2 gm twice daily to be taken on rising and at bedtime or Sucralfate 1 gm four times a day to be taken 1 hour before meals and at bedtime. Maximum daily dose is 8 gm but up to twelve weeks may be necessary in resistant cases. Pediatric population: The safety and efficacy of Sucralfate in children under 14 years of age has not been established. Elderly: There are no special dosage requirements for elderly patients but as with all medicines the lowest effective dose should be used. Prophylaxis of gastrointestinal hemorrhage from stress ulceration- Adults: The usual dose is Sucralfate 1 gm orally or via a nasogastric tube 4 to 6 times a day. To prevent clogging of the nasogastric tube flush with 10 ml of water following each administration. The duration of treatment for prophylaxis of stress ulceration must be individually determined. Treatment should be continued for as long as one or more of the risk factors for stress ulceration is present but normally not for more than 14 days.

Side effects

The most common adverse event was headache (3.4%) followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhea (1.1%), and urticaria (1.1%). The majority of patients who reported bezoars, had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. Episodes of hyperglycemia have been reported in diabetic patient.

Precautions and warnings

Sucralfate should only be used with caution in patients with renal dysfunction, due to the possibility of increased aluminium absorption. Sucralfate is not recommended for use in individuals on dialysis. In patients with severe or chronic renal impairment, Sucralfate should be used with extreme caution and only for short-term treatment. Small amounts of aluminium are absorbed through the gastrointestinal tract and aluminium may accumulate. Aluminium osteodystrophy, osteomalacia, encephalopathy and anaemia have been reported in patients with chronic renal impairment. For patients with impairment of renal function, laboratory testing such as aluminium, phosphate, calcium and alkaline phosphatase is recommended to be periodically performed due to excretion impairment. The concomitant use of other aluminium containing medications is not recommended in view of the enhanced potential for aluminium absorption and toxicity. Bezoars have been reported after administration of sucralfate mainly to severely ill patients in intensive care units. The majority of these patients (including neonates in whom sucralfate is not recommended) had underlying conditions that may predispose to bezoar formation (such as delayed gastric emptying due to surgery, drug therapy or diseases that reduce motility) or were receiving concomitant enteral tube feeding.

Pregnancy and lactation

Safety in pregnant women has not been established and Sucralfate should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Caution should be exercised when Sucralfate is administered to breast-feeding women.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250